Durantel David
INSERM, U871, Lyon, France.
Antivir Ther. 2010;15(3 Pt B):521-7. doi: 10.3851/IMP1551.
The emergence of hepatitis B virus (HBV) drug-resistant (and multidrug-resistant) strains during long-term therapy with nucleoside/nucleotide analogues is associated with treatment failure and, therefore, represents a clinical challenge. For clinicians, the close monitoring and management of resistance has become a key issue in clinical practice. For HBV virologists, the understanding of the mechanism of emergence of specific mutant strains in the viral quasispecies during treatment is also an important issue. If a particular viral strain can emerge in the quasispecies within a particular environment, it is probably because its fitness is superior to other strains. The present review focuses on viral fitness as well as viral infectivity, and in particular on technical means that are available to study this viral fitness in vitro and in animal models.
在核苷/核苷酸类似物长期治疗期间，乙型肝炎病毒（HBV）耐药（及多重耐药）毒株的出现与治疗失败相关，因此是一项临床挑战。对临床医生而言，耐药性的密切监测与管理已成为临床实践中的关键问题。对HBV病毒学家来说，了解治疗期间病毒准种中特定突变毒株的出现机制也是一个重要问题。如果特定病毒毒株能在特定环境下的准种中出现，很可能是因为其适应性优于其他毒株。本综述聚焦于病毒适应性以及病毒感染性，尤其关注可用于在体外和动物模型中研究这种病毒适应性的技术手段。
